Michael John Sumner - 15 May 2026 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Reporting relationship: Chief Medical Officer
Issuer ticker: INO
Reported as of: 15 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 May 2026, 16:04:56 UTC
Prior SEC filing: 01 Apr 2026
Next SEC filing: 21 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael John Sumner

Key filing fact

Michael John Sumner filed Form 4 for INOVIO PHARMACEUTICALS, INC. (INO) on 18 May 2026.

Key facts

This page summarizes Michael John Sumner's Form 4 filing for INOVIO PHARMACEUTICALS, INC. (INO).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 May 2026, 16:04.

Change

Previous filing in this sequence was filed on 01 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001936799 Primary reporting owner

Sumner Michael John

Relationship: Chief Medical Officer
Address: 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING
Signature: /s/ Michael John Sumner
Signature date: 18 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INO transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,385
Change %: +7.1%
Price
Shares after: 35,961
Date: 15 May 2026
Ownership: Direct
Footnotes: F1

INO transaction

Common Stock

Tax liability

Transaction value
Shares: -680
Change %: -1.9%
Price: $1.30^*
Shares after: 35,281
Date: 15 May 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INO transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: -2,385
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,385
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 7,156 restricted stock units was as follows: 2,386 shares vested on May 15, 2024; 2,385 shares vested on May 15, 2025; and 2,385 shares vested on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Footnote F2

The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.